Companion Diagnostics: Lessons Learned and the Path Forward Fromthe Programmed Death Ligand-1 Rollout.

* Context.--Programmed death ligand-1 (PD-L1) immunohistochemistry companion diagnostic assays play a crucial role as predictive markers in patients being considered for immune checkpoint inhibitor therapy. However, because of a convergence of several factors, including recognition of increased type...

Descripción completa

Detalles Bibliográficos
Publicado en:Archives of Pathology & Laboratory Medicine Vol. 147; no. 1; pp. 62 - 71
Autores principales: Willis, Joseph E., Eyerer, Frederick, Walk, Eric E., Vasalos, Patricia, Bradshaw, Georganne, Yohe, Sophia Louise, Laser, Jordan S.
Formato: research tables/charts Journal Article
Publicado: College of American Pathologists Jan2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=161073170&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 161073170
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00039985
        1FS
      jtl: Archives of Pathology & Laboratory Medicine
      issn: 00039985
      maglogo: N
    pubinfo:
      dt: Jan2023
      vid: 147
      iid: 1
      pid: 2550
      pub: College of American Pathologists
      place: Northfield, Illinois
    artinfo:
      ui:
        161073170
        161073170
        161073170
        10.5858/arpa.2021-0151-CP
        161073170
      ppf: 62
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Companion Diagnostics: Lessons Learned and the Path Forward Fromthe Programmed Death Ligand-1 Rollout.
      aug:
        au:
          Willis, Joseph E.
          Eyerer, Frederick
          Walk, Eric E.
          Vasalos, Patricia
          Bradshaw, Georganne
          Yohe, Sophia Louise
          Laser, Jordan S.
        affil: Department of Pathology, University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, Ohio
      sug:
        subj:
          College of American Pathologists
          Neoplasms Diagnosis
          Programmed Cell Death Ligand 1 Analysis
          Programmed Cell Death Protein 1 Receptor Analysis
          Stakeholder Participation
          Human
          Biological Markers
          Immunochemistry
          Immune Checkpoint Inhibitors
          Immunotherapy Methods
          Receptors, Cell Surface
          Implementation Science
      ab: * Context.--Programmed death ligand-1 (PD-L1) immunohistochemistry companion diagnostic assays play a crucial role as predictive markers in patients being considered for immune checkpoint inhibitor therapy. However, because of a convergence of several factors, including recognition of increased types of cancers susceptible to immunotherapy, increasing numbers of immune checkpoint inhibitors, and release of multiple PD-L1 immunohistochemistry antibodies with differing reporting systems, this complex testing environment has led to significant levels of confusion for pathologists and medical oncologists. Objective.--To identify which processes and procedures have contributed to the current challenges surrounding programmed death receptor-1 (PD-1)/PD-L1 companion diagnostics and to propose potential remedies to this issue. This is based upon input from key industrial stakeholders in conjunction with the College of American Pathologists Personalized Health Care Committee. Design.--A meeting of representatives of pharmaceutical and in vitro diagnostic companies along with the Personalized Health Care Committee reviewed the process of release of the PD-L1 companion diagnostic assays using a modified root cause analysis format. The modified root cause analysis envisioned an ideal circumstance of development and implementation of a companion diagnostic to identify shortcomings in the rollout of the PD-L1 assay and to suggest actions to improve future companion diagnostic assay releases. Results.--The group recommended improvements to key principles in companion diagnostics implementation related to multi-stakeholder communication, increased regulatory flexibility to incorporate postapproval medical knowledge, improved cross-disciplinary information exchange between medical oncology and pathology societies, and enhanced postmarket training programs. Conclusions.--The rapidly changing nature of and increasing complexity associated with companion diagnostics require a fundamental review of processes related to their design, implementation, and oversight.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N